Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 6;32(6):724-731.
doi: 10.1136/ijgc-2021-003227.

Sociodemographic characteristics and cervical cancer survival in different regions of the United States: a National Cancer Database study

Affiliations

Sociodemographic characteristics and cervical cancer survival in different regions of the United States: a National Cancer Database study

Michael D Toboni et al. Int J Gynecol Cancer. .

Abstract

Objective: To determine how sociodemographic factors impact cervical cancer survival in different geographic locations in the USA.

Methods: A retrospective cohort of patients with cervical cancer from January 1, 2004 to December 31, 2015 in the National Cancer Database (NCDB) was identified. Tumor characteristics as well as race, income, insurance type, and treating facility types were compared among nine geographic regions. χ2 tests and Cox regression were used to compare differences between regions; p values <0.05 were considered significant.

Results: A total of 48 787 patients were included. Survival was inferior in seven of nine regions for underinsured patients. In six regions survival was inferior for Medicaid and Medicare patients, respectively: Middle Atlantic: hazard ratio (HR) 1.25 and 1.22; South Atlantic: HR 1.41 and HR 1.22; East North Central: HR 1.36 and HR 1.25; East South Central: HR 1.37 and HR 1.25; West North Central: HR 1.67 and HR 1.42; West South Central: HR 1.44 and HR 1.46. In the Pacific region survival was inferior for Medicare patients (HR 1.35) but not inferior for Medicaid patients. Being uninsured was associated with worse survival in the South Atlantic (HR 1.23), East North Central (HR 1.23), East South Central (HR 1.56), and West South Central (HR 1.31) regions. Annual income level under $38 000 was associated with worse survival in the Middle Atlantic (HR 1.24), South Atlantic (HR 1.35), and East North Central (HR 1.49) regions. Lastly, when compared with academic research institutions, comprehensive community cancer centers had significantly worse survival in four of the nine regions.

Conclusions: Cervical cancer mortality is higher for women with a low income, underinsured (Medicaid or Medicare) or uninsured status, and decreased access to academic institutions in most US regions. An increase in cervical cancer mortality was associated with underinsured or uninsured populations in regions mainly located in the South and Midwest.

Keywords: Cervical Cancer; Cervix Uteri.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Nine National Cancer Database regions.
Figure 2
Figure 2
National Cancer Database regions with significantly worse survival among cervical cancer patients insured by Medicaid in different colors. Labeled states have not adopted, implemented, or only recently implemented the Medicaid expansion. Gray-blue states in the Northeast, Mountain and Pacific regions did not have inferior survival in Medicaid patients. No asterisk, have not adopted or implemented Medicaid expansion. *Adopted but not implemented the Medicaid expansion. **Adopted the Medicaid expansion within the last 6 months.

References

    1. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2020;24:102–31. - PMC - PubMed
    1. Howlader NNA, Krapcho M, Miller D, eds. SEER Cancer Statistics Review. Bethesda, MD: National Cancer Institute, 1975–2017.
    1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7–33 - PubMed
    1. Petrosky E, Bocchini JA, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2015;64:300–4. - PMC - PubMed
    1. Lei J, Ploner A, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med 2020;383:1340–8. - PubMed

Publication types